Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)

Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, causes chronic gastrointestinal symptoms and can lead to morbidity and mortality if uncontrolled or untreated. However, for patients with moderate-to-severe disease, currently available therapies do not induce or maintain remission in >50% of patients. This underscores the need for additional therapies. In this review, the authors detail the novel therapies vedolizumab, tofacitinib, and ustekinumab and delve into therapies which may come onto the market within the next 10 years, including JAK-1 inhibitors (filgotinib and upadacitinib), IL-23 inhibitors (guselkumab, mirikizumab, and risankizumab), the anti-β4β7 and anti-βEβ7 integrin monoclonal antibody etrolizumab, the sphingosine-1-phosphate subtypes 1 and 5 modulator ozanimod, and mesenchymal stem cells. Further studies are required before these emerging therapies gain approval.

Download Full-text

The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.16741 ◽

2021 ◽

Author(s):

Jie Wang ◽

Idan Goren ◽

Bo Yang ◽

Sinan Lin ◽

Jiannan Li ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Therapeutic Target ◽

Sphingosine 1 Phosphate ◽

Inflammatory Bowel

Download Full-text

Sphingosine-1-phosphate (S1P) signaling regulates the production of intestinal IgA and its potential role in the pathogenesis of canine inflammatory bowel disease

Journal of Veterinary Medical Science ◽

10.1292/jvms.19-0016 ◽

2019 ◽

Vol 81 (9) ◽

pp. 1249-1258 ◽

Cited By ~ 1

Author(s):

Maho NAKAZAWA ◽

Shingo MAEDA ◽

Nozomu YOKOYAMA ◽

Taisuke NAKAGAWA ◽

Tomohiro YONEZAWA ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Potential Role ◽

Sphingosine 1 Phosphate ◽

Inflammatory Bowel ◽

Intestinal Iga

Download Full-text

Modulation of sphingosine-1-phosphate in inflammatory bowel disease

Autoimmunity Reviews ◽

10.1016/j.autrev.2017.03.007 ◽

2017 ◽

Vol 16 (5) ◽

pp. 495-503 ◽

Cited By ~ 44

Author(s):

Laurent Peyrin-Biroulet ◽

Ronald Christopher ◽

Dominic Behan ◽

Cheryl Lassen

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Sphingosine 1 Phosphate ◽

Inflammatory Bowel

Download Full-text

Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation

Inflammatory Bowel Diseases ◽

10.1093/ibd/izz174 ◽

2019 ◽

Vol 26 (2) ◽

pp. 216-228 ◽

Cited By ~ 2

Author(s):

Thangaraj Karuppuchamy ◽

Christopher J Tyler ◽

Luke R Lundborg ◽

Tamara Pérez-Jeldres ◽

Abigail K Kimball ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Effective Alternative ◽

Receptor Agonists ◽

Therapeutic Alternative ◽

Sphingosine 1 Phosphate ◽

Inflammatory Bowel ◽

S1p Receptor ◽

S1p Lyase

Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymocyte maturation.

Download Full-text